April 2024

News from Strategic Alliance Partners of The American Journal of Managed Care.

Interview with Al B. Benson III, MD, FACP, FACCC, FASCO, professor of medicine at Northwestern University Feinberg School of Medicine.

An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab.

Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.